Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Allergan, Richter’s bipolar depression drug succeeds in key trial

Allergan and Gedeon Richter’s drug cariprazine to treat severe bipolar depression in adults met the main goal of a late-stage study.

Read More »

US FDA Accepts Regulatory Submission for Tagrisso in First-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca announced that the U.S. Food and Drug Administration accepted a supplemental New Drug Application for the use of Tagrisso (osimertinib) – a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with clinical activity against central nervous system metastases – in the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR mutations.

Read More »

Tiny stem cell companies close in on major heart disease goals

Athersys Inc. and Mesoblast Ltd. are beginning final-stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.

Read More »

Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration

Regeneron Pharmaceuticals Inc. and ISA Pharmaceuticals B.V. announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with the PD-1 antibody cemiplimab (REGN2810).

Read More »

Roche, Shire court fight escalates over hemophilia drug

Roche’s patent dispute with London-listed Shire over the Swiss drugmaker’s new hemophilia drug Hemlibra escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

Read More »

AbbVie, Pfizer Jump in on Newly Launched Jnana Therapeutics’ $50 Million Funding Round

Jnana Therapeutics launched with a $50 million Series A financing. Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

Read More »

Keytruda Fails Phase III Stomach Cancer Study

Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Read More »

Novo Nordisk wins EU panel’s backing for key diabetes drug

Novo Nordisk came closer to winning European approval for the company’s diabetes drug Ozempic, the Danish drugmaker’s largest growth prospect, when a European Medicines Agency experts’ panel issued a positive recommendation.

Read More »

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration allowed Alnylam Pharmaceuticals Inc. to restart clinical trials on a drug to treat patients with a rare bleeding disorder.

Read More »

Aclaris’ drug to treat skin growth gets FDA nod

Aclaris Therapeutics Inc.’s drug to treat a common type of skin growth called seborrheic keratoses received FDA clearance.

Read More »

Pfizer’s Xeljanz Gets FDA Nod As Joint Disease Treatment

The U.S. FDA approved two doses of Pfizer Inc.’s medicine Xeljanz for treating active psoriatic arthritis.

Read More »

Germany’s Merck in fresh bid to enter U.S. MS pill market

Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.

Read More »

reMYND Forges 350M+ Euros Tie-Up With Novo Nordisk

Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

Read More »

Teva Cuts 14,000 Jobs in Massive Reorganization

Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.

Read More »

Treating bumps and humps: Dubai opens $10 million camel hospital

Pristine operating theaters and state-of-the-art medical equipment are featured in a new Dubai hospital that opened – exclusively for camels.

Read More »

McCann Health & CARE Confront the Harsh Reality of Death by Overdose from Prescription Drugs

Jeremy Perrott, McCann Health Global Chief Creative Officer, created the film that is meant to be a wake-up call that delivers a shocking moment of truth, like a stinging slap across the face. The visual style of filming the teenage boy’s first-person point of view, delivers an immersive and immediate experience that shines a light on the danger of what can happen if parents do not take steps to create a prescription drug safe home.

Read More »

Agencies Should Tell Less, Listen More

In today’s world of healthcare advertising and marketing, should agencies do less telling and more listening? The answer is yes, according to new data on how well healthcare marketers think their agencies listen.

Read More »

Pfizer’s second biosimilar of J&J’s Remicade wins U.S. FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc.’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.

Read More »

Bumper crop of new drugs fails to lift big pharma R&D returns

2017 has shaped up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Read More »

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom